home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Small Study Suggests Anticonvulsant Drug Holds Promise As Therapy For Cocaine Abuse

  September, 30 2003 16:57
your information resource in human molecular genetics
A preliminary clinical trial funded by the National Institute on Drug Abuse, the National Institutes of Health, suggests that gamma vinyl-GABA (GVG) — a drug used to treat epilepsy — may offer a potentially effective treatment for cocaine addiction.

Researchers from New York University School of Medicine and Brookhaven National Laboratory in Upton, New York, report this week in the online version of the journal Synapse that a small, preliminary clinical trial conducted in Mexico showed this drug could cut cocaine use dramatically in people who had used cocaine daily for at least 3 years.

The data reported in this study support the need for a larger, double-blind, placebo-controlled trial to determine the true efficacy and safety of this drug for cocaine addiction.

Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at National Institute on Drug Abuse (NIDA).

Message posted by: Rashmi Nemade

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.